Biogen Q4 Earnings Beat Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy BIIB?
Source: seekingalpha
- Earnings Performance: Biogen reported a Q4 Non-GAAP EPS of $1.99, exceeding expectations by $0.36, indicating strong profitability despite revenue challenges.
- Revenue Decline: The company’s Q4 revenue of $2.28 billion represents a 7.3% year-over-year decline, yet it surpassed expectations by $80 million, showcasing resilience amid market pressures.
- 2026 Financial Guidance: Biogen anticipates a Non-GAAP diluted EPS for 2026 between $15.25 and $16.25, exceeding the consensus estimate of $14.95, reflecting confidence in future profitability.
- Revenue Outlook Adjustment: Although total revenue for 2026 is expected to decline by a mid-single digit percentage compared to 2025, this outlook is more conservative than the estimated -5.11% growth, indicating prudent financial management.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is 186.19 USD with a low forecast of 135.00 USD and a high forecast of 250.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
25 Analyst Rating
11 Buy
13 Hold
1 Sell
Moderate Buy
Current: 185.450
Low
135.00
Averages
186.19
High
250.00
Current: 185.450
Low
135.00
Averages
186.19
High
250.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biogen Set to Announce Q4 Earnings with Mixed Estimates
- Earnings Announcement Date: Biogen is set to release its Q4 earnings on February 6 before market open, with a consensus EPS estimate of $1.63, reflecting a significant year-over-year decline of 52.6%, which could negatively impact the stock price.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $2.2 billion, representing a 10.6% year-over-year decrease, indicating challenges the company faces amid increasing market competition and sluggish product sales.
- Historical Performance Review: Over the past two years, Biogen has exceeded EPS and revenue estimates 75% of the time, although recent EPS estimates have seen 11 upward revisions and 7 downward revisions, highlighting market uncertainty regarding its future performance.
- R&D Impact Analysis: Biogen expects Q4 IPR&D expenses to impact EPS by approximately $1.26 per share, a significant expenditure that may further compress profit margins and affect investor confidence.
See More
Biogen Shares Increase Despite Falling Multiple Sclerosis Revenue and Ongoing Declines
- Stock Performance: Biogen's stock experienced an increase on Friday despite facing declining sales.
- Drug Portfolio Issues: The company's drug portfolio showed poor performance in the fourth quarter, contributing to investor concerns.
See More
Biogen Q4 Earnings Beat Expectations
- Earnings Performance: Biogen reported a Q4 Non-GAAP EPS of $1.99, exceeding expectations by $0.36, indicating strong profitability despite revenue challenges.
- Revenue Decline: The company’s Q4 revenue of $2.28 billion represents a 7.3% year-over-year decline, yet it surpassed expectations by $80 million, showcasing resilience amid market pressures.
- 2026 Financial Guidance: Biogen anticipates a Non-GAAP diluted EPS for 2026 between $15.25 and $16.25, exceeding the consensus estimate of $14.95, reflecting confidence in future profitability.
- Revenue Outlook Adjustment: Although total revenue for 2026 is expected to decline by a mid-single digit percentage compared to 2025, this outlook is more conservative than the estimated -5.11% growth, indicating prudent financial management.
See More
Biogen Reports Strong Q4 2025 Earnings but Projects Revenue Decline for 2026
- Earnings Beat: Biogen reported $2.3 billion in Q4 2025 revenue, surpassing consensus estimates by $80 million, demonstrating resilience despite pressures on its multiple sclerosis product line.
- Alzheimer's Therapy Growth: The Alzheimer's therapy Leqembi, marketed with Eisai, generated nearly $134 million in global sales, reflecting approximately 54% year-over-year growth, indicating significant market potential in this therapeutic area.
- Multiple Sclerosis Revenue Decline: While Vumerity sales grew by 3%, Biogen's multiple sclerosis franchise revenue fell approximately 14% year-over-year to $917.2 million, highlighting increasing competition and challenges in this market segment.
- Cautious 2026 Outlook: Biogen projects a mid-single-digit percentage decline in revenue for 2026, primarily due to pressures on multiple sclerosis product revenues, although overall gross margins and R&D expenses are expected to remain stable.
See More
Biogen Beats Estimates and Initiates FY26 Outlook
- Earnings Beat: Biogen exceeded both top-line and bottom-line estimates in its Q4 earnings report, demonstrating resilience and growth potential in a competitive pharmaceutical landscape.
- FY26 Outlook Initiated: The company provided its first outlook for FY26, indicating a commitment to driving future growth through innovative drugs and strategic investments, reflecting management's confidence in long-term development despite challenges.
- Industry Conference Participation: At the 44th Annual J.P. Morgan Healthcare Conference, Biogen outlined its future R&D directions and market strategies, aiming to bolster investor confidence in the company's future trajectory.
- Positive Market Reaction: Investors reacted positively to Biogen's earnings report and outlook, with the stock price rising post-release, indicating market recognition of the company's growth potential moving forward.
See More
Movers in the Market: Amazon, Novo Nordisk, Molina, Roblox, Hub Group, and Others
- Stock Market Movement: Stock futures increased on Friday despite concerns regarding artificial intelligence spending.
- Big Tech Earnings Impact: Recent earnings reports from major technology companies did not alleviate fears related to AI investments.
See More
Biogen Set to Announce Q4 Earnings with Mixed Estimates
- Earnings Announcement Date: Biogen is set to release its Q4 earnings on February 6 before market open, with a consensus EPS estimate of $1.63, reflecting a significant year-over-year decline of 52.6%, which could negatively impact the stock price.
- Revenue Decline Forecast: The anticipated revenue for Q4 is $2.2 billion, representing a 10.6% year-over-year decrease, indicating challenges the company faces amid increasing market competition and sluggish product sales.
- Historical Performance Review: Over the past two years, Biogen has exceeded EPS and revenue estimates 75% of the time, although recent EPS estimates have seen 11 upward revisions and 7 downward revisions, highlighting market uncertainty regarding its future performance.
- R&D Impact Analysis: Biogen expects Q4 IPR&D expenses to impact EPS by approximately $1.26 per share, a significant expenditure that may further compress profit margins and affect investor confidence.
See More
Biogen Shares Increase Despite Falling Multiple Sclerosis Revenue and Ongoing Declines
- Stock Performance: Biogen's stock experienced an increase on Friday despite facing declining sales.
- Drug Portfolio Issues: The company's drug portfolio showed poor performance in the fourth quarter, contributing to investor concerns.
See More
Biogen Q4 Earnings Beat Expectations
- Earnings Performance: Biogen reported a Q4 Non-GAAP EPS of $1.99, exceeding expectations by $0.36, indicating strong profitability despite revenue challenges.
- Revenue Decline: The company’s Q4 revenue of $2.28 billion represents a 7.3% year-over-year decline, yet it surpassed expectations by $80 million, showcasing resilience amid market pressures.
- 2026 Financial Guidance: Biogen anticipates a Non-GAAP diluted EPS for 2026 between $15.25 and $16.25, exceeding the consensus estimate of $14.95, reflecting confidence in future profitability.
- Revenue Outlook Adjustment: Although total revenue for 2026 is expected to decline by a mid-single digit percentage compared to 2025, this outlook is more conservative than the estimated -5.11% growth, indicating prudent financial management.
See More
Biogen Reports Strong Q4 2025 Earnings but Projects Revenue Decline for 2026
- Earnings Beat: Biogen reported $2.3 billion in Q4 2025 revenue, surpassing consensus estimates by $80 million, demonstrating resilience despite pressures on its multiple sclerosis product line.
- Alzheimer's Therapy Growth: The Alzheimer's therapy Leqembi, marketed with Eisai, generated nearly $134 million in global sales, reflecting approximately 54% year-over-year growth, indicating significant market potential in this therapeutic area.
- Multiple Sclerosis Revenue Decline: While Vumerity sales grew by 3%, Biogen's multiple sclerosis franchise revenue fell approximately 14% year-over-year to $917.2 million, highlighting increasing competition and challenges in this market segment.
- Cautious 2026 Outlook: Biogen projects a mid-single-digit percentage decline in revenue for 2026, primarily due to pressures on multiple sclerosis product revenues, although overall gross margins and R&D expenses are expected to remain stable.
See More
Biogen Beats Estimates and Initiates FY26 Outlook
- Earnings Beat: Biogen exceeded both top-line and bottom-line estimates in its Q4 earnings report, demonstrating resilience and growth potential in a competitive pharmaceutical landscape.
- FY26 Outlook Initiated: The company provided its first outlook for FY26, indicating a commitment to driving future growth through innovative drugs and strategic investments, reflecting management's confidence in long-term development despite challenges.
- Industry Conference Participation: At the 44th Annual J.P. Morgan Healthcare Conference, Biogen outlined its future R&D directions and market strategies, aiming to bolster investor confidence in the company's future trajectory.
- Positive Market Reaction: Investors reacted positively to Biogen's earnings report and outlook, with the stock price rising post-release, indicating market recognition of the company's growth potential moving forward.
See More
Movers in the Market: Amazon, Novo Nordisk, Molina, Roblox, Hub Group, and Others
- Stock Market Movement: Stock futures increased on Friday despite concerns regarding artificial intelligence spending.
- Big Tech Earnings Impact: Recent earnings reports from major technology companies did not alleviate fears related to AI investments.
See More
